Highlights Hyloris Pharmaceuticals SA

Stocks

HYL

BE0974363955

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 04:44:46 2026-06-15 am EDT			5-day change	1st Jan Change
4.720 ^EUR	-0.63%		-5.60%	-30.99%

Mar. 25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT

Highlights

Mar. 25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT
Dec. 31	Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug	MT
Dec. 29	Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution	MT
Dec. 12	Hyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder Therapy	MT
25-10-27	Hyloris Pharmaceuticals Wins Exclusive Chinese Licensing, Distribution Deal for Iron Deficiency Anemia Treatment	MT
25-09-25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-23	Hyloris to Partially Fund Suramin IV Development for Sleeping Sickness	MT
25-06-04	Hyloris Partner Avenacy's Intravenous Tranexamic Acid Application Gets US FDA Nod	MT
25-05-22	Hyloris Pharmaceuticals Lands Exclusive Commercialization Deal for Xtraza Oral Rinse	MT
25-05-13	Hyloris Pharmaceuticals Signs Commercialization Deals for Valacyclovir	MT
25-03-30	AFT Pharmaceuticals Collaborates with Hyloris Pharmaceuticals to Develop A Novel Innovative Injectable Iron Deficiency Therapy	CI
25-02-25	US FDA Accepts Drug Application for Hyloris Pharmaceuticals' Oral Suspension	MT
25-02-03	Hyloris Pharmaceuticals Lands Exclusive UK Distribution Deal for Xtraza	MT
25-01-14	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-15	Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-05	Belgian finance regulator issues warning about Hyloris Pharmaceuticals	RE
24-03-14	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
24-03-14	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-14	Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	CI
24-01-30	Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis	CI
24-01-18	Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus	CI
23-12-21	AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals	CI
23-10-26	Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada	CI
23-10-18	Hyloris Pharma wins US FDA approval for pain treatment	RE